# Clinical burden of dry eye disease in patients with ocular graft versus host disease

**Authors:** Cherie B. Nau, Muriel M. Schornack, Jennifer S. Harthan, Jennifer S. Fogt, Amy C. Nau, William J. Hogan, Ellen S. Shorter

PMC · DOI: 10.20935/acadmedhealth8096 · Academia medicine and health · 2026-03-03

## TL;DR

This study explores how dry eye disease affects patients with ocular graft versus host disease, highlighting the symptoms and treatment challenges they face.

## Contribution

The study provides patient-reported insights into the clinical burden of dry eye in oGVHD patients.

## Key findings

- The most common symptom reported was a sandy or gritty feeling in the eyes.
- Patients used an average of four treatments despite experiencing nine symptoms on average.
- Most patients received care from eye care professionals rather than hematologists.

## Abstract

Ocular graft-versus-host disease (oGVHD) is a frequent complication after hematopoietic stem cell transplant, with dry eye being the most common presentation. Patient experience with dry eye from oGVHD may negatively affect quality of life. The purpose of this study was to evaluate patients’ perspectives on the symptoms, treatments, and care burdens associated with dry eye from oGVHD.

An electronic questionnaire was sent to patients with dry eye asking about their diagnoses, symptoms, treatments, and experiences associated with dry eye.

Of the 639 patients who responded to the questionnaire, 79 reported having dry eye from oGVHD and were included in the analysis. The mean (SD) age of these patients was 55 (10) years (range, 22–73 years; n = 75). Of the patients who reported their sex (n = 78), 32 were male, and 46 were female. The most common ocular symptom was a sandy or gritty feeling (n = 68, 86%). Patients reported a mean (SD) of nine (2) symptoms, despite using four (2) treatments. The most common initial treatment was artificial tears (n = 71, 90%). Most patients (68/75, 91%) reported receiving oGVHD care from an eye care professional (e.g., ophthalmologist or optometrist), whereas a few (4/75, 5%) received oGVHD care from a hematologist.

Dry eye symptoms and treatments, along with the associated time and financial costs required, are a burden to patients with oGVHD. These patients should be evaluated by a knowledgeable eye care professional to best treat and manage their disease.

## Full-text entities

- **Diseases:** keratoconjunctivitis sicca (MESH:D007638), blepharitis (MESH:D001762), fogging (MESH:D005222), meibomian gland dysfunction (MESH:D000080343), corneal perforation (MESH:D057112), corneal irregularity (MESH:D008599), dry (MESH:D015352), corneal epithelial damage (MESH:D009375), photophobia (MESH:D020795), cicatricial conjunctivitis (MESH:D003231), punctal occlusion (MESH:D001157), atrophy of the lacrimal gland (MESH:C562407), artificial tears (MESH:D012167), Chronic Ocular GVHD (MESH:D000092122), artificial (MESH:D060437), cancer (MESH:D009369), irritation (MESH:D001523), OSDI (MESH:D010534), GVHD (MESH:D006086), eyes (MESH:D005134), eye pain (MESH:D058447), fibrosis (MESH:D005355), complication (MESH:D008107), Inflammatory (MESH:D007249), periorbital hyperpigmentation (MESH:D017495), pain (MESH:D010146), Blurred or compromised vision (MESH:D014786), loss of corneal sensation (MESH:D003316), keratoconjunctivitis (MESH:D007637)
- **Chemicals:** lipid (MESH:D008055), fluorescein (MESH:D019793), cyclosporine (MESH:D016572), saline (MESH:D012965)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12951619/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12951619/full.md

## References

38 references — full list in the complete paper: https://tomesphere.com/paper/PMC12951619/full.md

---
Source: https://tomesphere.com/paper/PMC12951619